Cabazitaxel

• CAT Number: I002372
• CAS Number: 183133-96-2
• Molecular Formula: C45H57NO14
• Molecular Weight: 835.9
• Purity: ≥95%
• Target: Microtubule/Tubulin
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• InChIKey: BMQGVNUXMIRLCK-OAGWZNDDSA-N
• SMILES: CC(C1=C(C)[C@@H](OC([C@H](O)[C@@H](NC(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C3)(C)[C@]3(O)[C@@H](OC(C4=CC=CC=C4)=O)[C@@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]6OC)([H])[C@]6(C)C([C@@H]1OC)=O

Cabazitaxel (CAT: I002372) is a semi-synthetic taxane chemotherapy agent that belongs to the class of microtubule-targeting drugs. It acts by inhibiting microtubule depolymerization and promoting microtubule assembly, resulting in the disruption of cellular processes such as mitosis and cell division. Cabazitaxel is primarily used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after docetaxel-based chemotherapy. It is administered intravenously and has shown improved overall survival and progression-free survival in clinical trials. Cabazitaxel offers an important therapeutic option for patients with advanced prostate cancer who have limited treatment alternatives.

Reference

1: Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the
management of advanced prostate cancer. Clin Interv Aging. 2010 Dec 3;5:395-402.
doi: 10.2147/CIA.S14570. Review. PubMed PMID: 21152241; PubMed Central PMCID:
PMC2998247.

2: Hussar DA, Daniels WL. New drugs: Sipuleucel-T, cabazitaxel, and collagenase
clostridium histolyticum. J Am Pharm Assoc (2003). 2010 Nov-Dec;50(6):772-5. doi:
10.1331/JAPhA.2010.10542. PubMed PMID: 21071329.

3: Wilkes GM. Cabazitaxel, a taxane for men with hormone-refractory metastatic
prostate cancer. Oncology (Williston Park). 2010 Oct;24(10 Suppl):46-8. PubMed
PMID: 21275327.

4: Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug
Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. PubMed PMID: 20811375.